{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:21:11Z","timestamp":1790403671535,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T00:00:00Z","timestamp":1348531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s40262-012-0010-0","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T20:34:16Z","timestamp":1355776456000},"page":"823-829","source":"Crossref","is-referenced-by-count":71,"title":["Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma"],"prefix":"10.1007","volume":"51","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ievgenii I.","family":"Karamanesht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Domnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryna Y.","family":"Kyselyova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna V.","family":"Vilchevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim A.","family":"Doronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie-Lee","family":"Esseltine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Skee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cakana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Deraedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"key":"10_CR1","unstructured":"Janssen-Cilag International N.V. VELCADE\u00ae (bortezomib): summary of product characteristics. Beerse: Janssen-Cilag International N.V.; 2009."},{"key":"10_CR2","unstructured":"Millennium Pharmaceuticals Inc. VELCADE\u00ae (bortezomib) for injection: prescribing information. Rev. 13. Cambridge: Millennium Pharmaceuticals Inc.; 2012."},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431\u201340.","journal-title":"Lancet Oncol"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3324\/haematol.13285","volume":"93","author":"P Moreau","year":"2008","unstructured":"Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. 2008;93:1908\u201311.","journal-title":"Haematologica"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San MJ, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46:673\u201383.","journal-title":"Clin Chem"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768\u201373.","journal-title":"Blood"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00003088-200948030-00006","volume":"48","author":"DI Quinn","year":"2009","unstructured":"Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin\u2019s lymphoma or multiple myeloma. Clin Pharmacokinet. 2009;48:199\u2013209.","journal-title":"Clin Pharmacokinet"},{"issue":"Pt 2","key":"10_CR9","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.clinthera.2009.11.012","volume":"31","author":"K Venkatakrishnan","year":"2009","unstructured":"Venkatakrishnan K, Rader M, Ramanathan RK, Ramalingam S, Chen E, Riordan W, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug\u2013drug interaction study. Clin Ther. 2009;31(Pt 2):2444\u201358.","journal-title":"Clin Ther"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2165\/11594410-000000000-00000","volume":"50","author":"A Hellmann","year":"2011","unstructured":"Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, et al. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin\u2019s lymphoma. Clin Pharmacokinet. 2011;50:781\u201391.","journal-title":"Clin Pharmacokinet"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00280-011-1637-5","volume":"68","author":"TB Leal","year":"2011","unstructured":"Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, et al. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol. 2011;68:1439\u201347.","journal-title":"Cancer Chemother Pharmacol"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-11-2873","volume":"18","author":"PM LoRusso","year":"2012","unstructured":"LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18:2954\u201363.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-012-0010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-012-0010-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-012-0010-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-012-0010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T22:09:13Z","timestamp":1595110153000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-012-0010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s40262-012-0010-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]}}}